Effects of levemopamil on neurologic and histologic outcome after cardiac arrest in cats

J. E. Fleischer, K. Nakakimura, J. C. Drummond, M. S. Scheller, Mark Zornow, Marjorie Grafe, H. M. Shapiro

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background and Methods: A study was performed to examine the effects of the calcium-channel blocker levemopamil on neurologic outcome and neuropathology in a clinically relevant model of complete global cerebral ischemia (ventricular fibrillation in cats). Levemopamil was administered to cats starting 5 mins after resuscitation from 14 mins of cardiac arrest. In a ''blinded'' manner, 46 animals received levemopamil 1 mg/kg over 15 mins followed by 10 μg/kg·min for 16 hrs or vehicle. In a nonblinded manner, eight additional animals were pretreated with levemopamil beginning 45 mins before cardiac arrest. After resuscitation, levemopamil was infused at 10 μg/kg·min for 16 hrs. Animals in all three groups remained sedated, paralyzed, and mechanically ventilated for 24 to 30 hrs after resuscitation. Neurologic examinations were performed at 2, 4, and 7 days after resuscitation. Thirty-five cats were entered into data analysis (16 levemopamil posttreated, 14 vehicle-treated, and 5 levemopamil pretreated). Results: Neurologic deficit scores and overall neuropathologic scores did not differ among groups at any interval after resuscitation. However, the occipital cortex and CA1 region of the pretreated animals showed less severe damage than was observed in the animals that received levemopamil or vehicle, starting after resuscitation (p <.01). Conclusions: Postarrest administration of levemopamil was not associated with improved neurologic or neuropathologic outcome. However, the data suggest that prearrest administration may result in regionally selective improvement in neuropathology.

Original languageEnglish (US)
Pages (from-to)126-134
Number of pages9
JournalCritical Care Medicine
Volume20
Issue number1
StatePublished - 1992
Externally publishedYes

Fingerprint

Heart Arrest
Nervous System
Cats
Resuscitation
emopamil
Occipital Lobe
Neurologic Examination
Calcium Channel Blockers
Ventricular Fibrillation
Neurologic Manifestations
Brain Ischemia

Keywords

  • Blood gas analysis
  • Calcium-channel blockers
  • Cardiac arrest
  • Cerebral ischemia
  • Neurologic examination
  • Resuscitation
  • Ventilation, mechanical
  • Ventricular fibrillation

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Fleischer, J. E., Nakakimura, K., Drummond, J. C., Scheller, M. S., Zornow, M., Grafe, M., & Shapiro, H. M. (1992). Effects of levemopamil on neurologic and histologic outcome after cardiac arrest in cats. Critical Care Medicine, 20(1), 126-134.

Effects of levemopamil on neurologic and histologic outcome after cardiac arrest in cats. / Fleischer, J. E.; Nakakimura, K.; Drummond, J. C.; Scheller, M. S.; Zornow, Mark; Grafe, Marjorie; Shapiro, H. M.

In: Critical Care Medicine, Vol. 20, No. 1, 1992, p. 126-134.

Research output: Contribution to journalArticle

Fleischer, JE, Nakakimura, K, Drummond, JC, Scheller, MS, Zornow, M, Grafe, M & Shapiro, HM 1992, 'Effects of levemopamil on neurologic and histologic outcome after cardiac arrest in cats', Critical Care Medicine, vol. 20, no. 1, pp. 126-134.
Fleischer, J. E. ; Nakakimura, K. ; Drummond, J. C. ; Scheller, M. S. ; Zornow, Mark ; Grafe, Marjorie ; Shapiro, H. M. / Effects of levemopamil on neurologic and histologic outcome after cardiac arrest in cats. In: Critical Care Medicine. 1992 ; Vol. 20, No. 1. pp. 126-134.
@article{76b232ae412b4df8b7245f169692ae46,
title = "Effects of levemopamil on neurologic and histologic outcome after cardiac arrest in cats",
abstract = "Background and Methods: A study was performed to examine the effects of the calcium-channel blocker levemopamil on neurologic outcome and neuropathology in a clinically relevant model of complete global cerebral ischemia (ventricular fibrillation in cats). Levemopamil was administered to cats starting 5 mins after resuscitation from 14 mins of cardiac arrest. In a ''blinded'' manner, 46 animals received levemopamil 1 mg/kg over 15 mins followed by 10 μg/kg·min for 16 hrs or vehicle. In a nonblinded manner, eight additional animals were pretreated with levemopamil beginning 45 mins before cardiac arrest. After resuscitation, levemopamil was infused at 10 μg/kg·min for 16 hrs. Animals in all three groups remained sedated, paralyzed, and mechanically ventilated for 24 to 30 hrs after resuscitation. Neurologic examinations were performed at 2, 4, and 7 days after resuscitation. Thirty-five cats were entered into data analysis (16 levemopamil posttreated, 14 vehicle-treated, and 5 levemopamil pretreated). Results: Neurologic deficit scores and overall neuropathologic scores did not differ among groups at any interval after resuscitation. However, the occipital cortex and CA1 region of the pretreated animals showed less severe damage than was observed in the animals that received levemopamil or vehicle, starting after resuscitation (p <.01). Conclusions: Postarrest administration of levemopamil was not associated with improved neurologic or neuropathologic outcome. However, the data suggest that prearrest administration may result in regionally selective improvement in neuropathology.",
keywords = "Blood gas analysis, Calcium-channel blockers, Cardiac arrest, Cerebral ischemia, Neurologic examination, Resuscitation, Ventilation, mechanical, Ventricular fibrillation",
author = "Fleischer, {J. E.} and K. Nakakimura and Drummond, {J. C.} and Scheller, {M. S.} and Mark Zornow and Marjorie Grafe and Shapiro, {H. M.}",
year = "1992",
language = "English (US)",
volume = "20",
pages = "126--134",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Effects of levemopamil on neurologic and histologic outcome after cardiac arrest in cats

AU - Fleischer, J. E.

AU - Nakakimura, K.

AU - Drummond, J. C.

AU - Scheller, M. S.

AU - Zornow, Mark

AU - Grafe, Marjorie

AU - Shapiro, H. M.

PY - 1992

Y1 - 1992

N2 - Background and Methods: A study was performed to examine the effects of the calcium-channel blocker levemopamil on neurologic outcome and neuropathology in a clinically relevant model of complete global cerebral ischemia (ventricular fibrillation in cats). Levemopamil was administered to cats starting 5 mins after resuscitation from 14 mins of cardiac arrest. In a ''blinded'' manner, 46 animals received levemopamil 1 mg/kg over 15 mins followed by 10 μg/kg·min for 16 hrs or vehicle. In a nonblinded manner, eight additional animals were pretreated with levemopamil beginning 45 mins before cardiac arrest. After resuscitation, levemopamil was infused at 10 μg/kg·min for 16 hrs. Animals in all three groups remained sedated, paralyzed, and mechanically ventilated for 24 to 30 hrs after resuscitation. Neurologic examinations were performed at 2, 4, and 7 days after resuscitation. Thirty-five cats were entered into data analysis (16 levemopamil posttreated, 14 vehicle-treated, and 5 levemopamil pretreated). Results: Neurologic deficit scores and overall neuropathologic scores did not differ among groups at any interval after resuscitation. However, the occipital cortex and CA1 region of the pretreated animals showed less severe damage than was observed in the animals that received levemopamil or vehicle, starting after resuscitation (p <.01). Conclusions: Postarrest administration of levemopamil was not associated with improved neurologic or neuropathologic outcome. However, the data suggest that prearrest administration may result in regionally selective improvement in neuropathology.

AB - Background and Methods: A study was performed to examine the effects of the calcium-channel blocker levemopamil on neurologic outcome and neuropathology in a clinically relevant model of complete global cerebral ischemia (ventricular fibrillation in cats). Levemopamil was administered to cats starting 5 mins after resuscitation from 14 mins of cardiac arrest. In a ''blinded'' manner, 46 animals received levemopamil 1 mg/kg over 15 mins followed by 10 μg/kg·min for 16 hrs or vehicle. In a nonblinded manner, eight additional animals were pretreated with levemopamil beginning 45 mins before cardiac arrest. After resuscitation, levemopamil was infused at 10 μg/kg·min for 16 hrs. Animals in all three groups remained sedated, paralyzed, and mechanically ventilated for 24 to 30 hrs after resuscitation. Neurologic examinations were performed at 2, 4, and 7 days after resuscitation. Thirty-five cats were entered into data analysis (16 levemopamil posttreated, 14 vehicle-treated, and 5 levemopamil pretreated). Results: Neurologic deficit scores and overall neuropathologic scores did not differ among groups at any interval after resuscitation. However, the occipital cortex and CA1 region of the pretreated animals showed less severe damage than was observed in the animals that received levemopamil or vehicle, starting after resuscitation (p <.01). Conclusions: Postarrest administration of levemopamil was not associated with improved neurologic or neuropathologic outcome. However, the data suggest that prearrest administration may result in regionally selective improvement in neuropathology.

KW - Blood gas analysis

KW - Calcium-channel blockers

KW - Cardiac arrest

KW - Cerebral ischemia

KW - Neurologic examination

KW - Resuscitation

KW - Ventilation, mechanical

KW - Ventricular fibrillation

UR - http://www.scopus.com/inward/record.url?scp=0026604645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026604645&partnerID=8YFLogxK

M3 - Article

C2 - 1729030

AN - SCOPUS:0026604645

VL - 20

SP - 126

EP - 134

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 1

ER -